Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares, rose in value, with the stock price down by -5.32% to the previous day’s close as strong demand from buyers drove the stock to $1.78.
Actively observing the price movement in the last trading, the stock closed the session at $1.88. The PE ratio was 2.53 over 12-month period. Referring to stock’s 52-week performance, its high was $30.50, and the low was $1.85. On the whole, AMLX has fluctuated by -35.04% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 106.13M, with a low estimate of 72M and a high estimate of 114.32M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 98.35M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AMLX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AMLX currently trading nearly -24.03% and -76.85% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 19.70, while the 7-day volatility ratio is showing 6.97% which for the 30-day chart, stands at 7.55%. Furthermore, Amylyx Pharmaceuticals Inc (AMLX)’s beta value is -0.73, and its average true range (ATR) is 0.34.
A comparison of Amylyx Pharmaceuticals Inc (AMLX) with its peers suggests the former has fared considerably weaker in the market. AMLX showed an intraday change of -5.32% in last session, and over the past year, it shrunk by -93.98%%.
Data on historical trading for Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) indicates that the trading volumes over the past 3 months, they’ve averaged 3.25 million. According to company’s latest data on outstanding shares, there are 67.71 million shares outstanding.
Nearly 30.75% of Amylyx Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 89.16% of the company’s shares. The stock has fallen by -87.91% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AMLX stock heading into the next quarter.
